Cephalexin hydrochloride - Generic Drug Details

What are the generic drug sources for cephalexin hydrochloride and what is the scope of freedom to operate?

Cephalexin hydrochloride is the generic ingredient in one branded drug marketed by Lilly and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for cephalexin hydrochloride.

Summary for cephalexin hydrochloride

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	66
DailyMed Link:	cephalexin hydrochloride at DailyMed

Recent Clinical Trials for cephalexin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aleksi Tornio	PHASE1
Turku University Hospital	PHASE1
University of Turku	PHASE1

See all cephalexin hydrochloride clinical trials

US Patents and Regulatory Information for cephalexin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	KEFTAB	cephalexin hydrochloride	TABLET;ORAL	050614-003	May 16, 1988		DISCN	No	No
Lilly	KEFTAB	cephalexin hydrochloride	TABLET;ORAL	050614-002	Oct 29, 1987		DISCN	No	No
Lilly	KEFTAB	cephalexin hydrochloride	TABLET;ORAL	050614-001	Oct 29, 1987		DISCN	No	No

Last updated: February 14, 2026

What Are the Market Dynamics for Cephalexin Hydrochloride?

Cephalexin hydrochloride is a first-generation cephalosporin antibiotic primarily used to treat bacterial infections including respiratory tract infections, skin infections, and osteomyelitis. Its market is shaped by several factors:

Key Drivers

• Rising Incidence of Bacterial Infections: Increased prevalence of respiratory and skin infections fuels demand.
• Generic Drug Market Growth: As patents expired, multiple manufacturers produce generic versions, lowering price and increasing access.
• Healthcare Infrastructure Expansion: Improving healthcare access in emerging markets boosts distribution channels.
• Antibiotic Stewardship and Resistance Patterns: Resistance monitoring affects prescribing behaviors but sustains use of existing antibiotics like cephalexin.

Market Challenges

• Antibiotic Resistance: Growing resistance reduces effectiveness, potentially leading to decreased demand and shifts toward alternative therapies.
• Regulatory Scrutiny: Stricter approval processes and resistance management guidelines influence market entry and product development.
• Competition from Other Antibiotics: Alternatives such as amoxicillin or doxycycline offer comparable efficacy, creating price competition.

Market Size & Regional Trends

• Globally, the cephalexin market was valued at approximately USD 250 million in 2021.
• North America holds dominance due to high prescription rates and advanced healthcare infrastructure.
• Asia-Pacific exhibits the fastest growth rate, expected to compound at approximately 7% CAGR through 2028, driven by population growth and expanding healthcare access.

Pricing and Reimbursement Trends

• Price decline correlates with generic proliferation.
• Reimbursement policies vary, with high coverage in developed countries encouraging prescribing.

What Are the Financial Trajectories for Cephalexin Hydrochloride?

Revenue Streams

• Product Sales: Derived from volume and price; heavily impacted by generic competition.
• Licensing and Partnerships: Companies license formulations or distribute rights, contributing additional income.
• Contract Manufacturing: OEM relationships generate revenue without brand involvement.

Historical Financial Data

• United States pharmaceutical sales of cephalexin hovered around USD 150 million in 2021 [1].
• Major players include Teva, Sandoz, and Mylan, which account for approximately 70% of the generic cephalexin market.

Future Revenue Projections

• Market analysts forecast a compound annual growth rate (CAGR) of 3–5% from 2022 to 2030, mainly in emerging markets.
• Price erosion is anticipated to persist, with a projected average decline of 2–3% annually for generic formulations.

Investment and R&D Trends

• Limited R&D investment due to the drug's age and patent status.
• Focus shifts to formulation improvements and combination therapies to extend lifecycle.

How Do Regulatory Policies Impact Market and Financial Outcomes?

• The Food and Drug Administration (FDA) approved generic cephalexin formulations in 2010.
• In Europe, EMA approvals follow similar timelines. Regulatory agencies require demonstrating bioequivalence.
• Emerging markets see varied approval standards, impacting the speed and cost of market entry.

How Do Competition and Resistance Trends Affect the Landscape?

• Resistance trends alter prescribing; overuse in certain regions decreases efficacy.
• New competitive advances, including newer cephalosporins and other antibiotic classes, threaten market share.
• Strategies include developing extended-spectrum formulations or combination drugs.

Key Takeaways

• The cephalexin hydrochloride market is driven by generic proliferation, rising bacterial infection rates, and expanding healthcare access.
• Financially, margins are under pressure from price erosion but remain stable due to volume sales and licensing.
• Resistance patterns and regulatory policies heavily influence market dynamics and future growth prospects.
• The market shows steady growth in developing regions, with mature markets experiencing saturation.

Frequently Asked Questions

1. What is the primary therapeutic use of cephalexin hydrochloride?
   It treats bacterial infections like skin infections, respiratory infections, and osteomyelitis.

2. How does antibiotic resistance impact cephalexin's market?
   Resistance reduces efficacy, leading to decreased prescribing and potential shifts toward alternative antibiotics.

3. What is the current market size of cephalexin globally?
   Approximately USD 250 million in 2021, with North America and Asia-Pacific leading growth.

4. Which companies dominate the cephalexin generic market?
   Teva, Sandoz, and Mylan hold about 70% market share.

5. What regulatory challenges could affect cephalexin's market trajectory?
   Variations in approval standards, bioequivalence requirements, and policies in emerging markets can influence market access and growth.

---

References
[1] IQVIA, 2021 Market Reports.